Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study

被引：132

作者：

Duruisseaux, Michael ^{[1
]}

Besse, Benjamin ^{[2
]}

Cadranel, Jacques ^{[3
]}

Perol, Maurice ^{[4
]}

Mennecier, Bertrand ^{[5
]}

Bigay-Game, Laurence ^{[6
]}

Descourt, Renaud ^{[7
]}

Dansin, Eric ^{[8
]}

Audigier-Valette, Clarisse ^{[9
]}

Moreau, Lionel ^{[10
]}

Hureaux, Jose ^{[11
]}

Veillon, Remi ^{[12
]}

Otto, Josiane ^{[13
]}

Madroszyk-Flandin, Anne ^{[14
]}

Cortot, Alexis ^{[15
]}

Guichard, Francois ^{[16
]}

Boudou-Rouquette, Pascaline ^{[17
]}

Langlais, Alexandra ^{[18
]}

Missy, Pascale ^{[19
]}

Morin, Franck ^{[19
]}

Moro-Sibilot, Denis ^{[1
]}

机构：

[1] Ctr Hosp Univ Grenoble Alpes, Chest Dept, Thorac Oncol Unit, Grenoble, France

[2] Dept Med Oncol, Gustave Roussy, Villejuif, France

[3] Tenon Hosp, AP HP, Chest Dept, Paris, France

[4] Leon Berard Canc Ctr, Lyon, France

[5] CHU Strasbourg, Chest Dept, Strasbourg, France

[6] Larrey Hosp, Chest Dept, Toulouse, France

[7] CHU Brest, Brest, France

[8] Oscar Lambret Canc Ctr, Dept Med Oncol, Lille, France

[9] Ctr Hosp St Musse, Toulon, France

[10] Ctr Hosp Gen Colmar, Louis Pasteur Hosp, Chest Dept, Colmar, France

[11] CHU Angers, Chest Dept, Angers, France

[12] Ctr Hosp Univ Bordeaux, Dept Resp Dis, Pessac, France

[13] Antoine Lacassagne Canc Ctr, Nice, France

[14] Paoli Calmettes Inst, Marseille, France

[15] CHU Lille, Thorac Oncol Unit, Lille, France

[16] Polyclin Bordeaux Nord Aquitaine, Dept Med Oncol, Bordeaux, France

[17] Cochin Port Royal Hosp, AP HP, Dept Med Oncol, Paris, France

[18] French Cooperat Thorac Intergrp, Dept Biostat, Paris, France

[19] French Cooperat Thorac Intergrp, Clin Res Unit, Paris, France

来源：

ONCOTARGET | 2017年 / 8卷 / 13期

关键词：

lung cancer; ALK; crizotinib; ceritinib; alectinib; OLIGOPROGRESSIVE DISEASE; CLINICAL BENEFIT; CHEMOTHERAPY; PROGRESSION; PHARMACOKINETICS; THERAPY; RECHALLENGE; ALECTINIB; SAFETY; GENE;

D O I：

10.18632/oncotarget.15746

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Overall survival (OS) with the anaplastic lymphoma kinase (ALK) inhibitor (ALKi) crizotinib in a large population of unselected patients with ALK-positive non-small-cell lung cancer (NSCLC) is not documented. We sought to assess OS with crizotinib in unselected ALK-positive NSCLC patients and whether post-progression systemic treatments affect survival outcomes. ALK-positive NSCLC patients receiving crizotinib in French expanded access programs or as approved drug were enrolled. We collected clinical and survival data, RECIST-defined progressive disease (PD) and post-PD systemic treatment efficacy. We performed multivariable analysis of OS from crizotinib initiation and PD under crizotinib. At time of analysis, 209 (65.7%) of the 318 included patients had died. Median OS with crizotinib was 16.6 months. The line of crizotinib therapy did not impact survival outcomes. Of the 263 patients with PD, 105 received best supportive care, 74 subsequent drugs other than next-generation ALKi and 84 next-generation ALKi. Next-generation ALKi treatment correlated with better survival outcomes in multivariate analysis. These patients had a median post-PD survival of 25.0 months and median OS from metastatic disease diagnosis of 89.6 months. Unselected ALK-positive NSCLC patients achieve good survival outcomes with crizotinib therapy. Next-generation ALKi may provide survival improvement after PD under crizotinib.

引用

页码：21903 / 21917

页数：15

共 28 条

[1] Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) [J].

Barlesi, Fabrice ;

Mazieres, Julien ;

Merlio, Jean-Philippe ;

Debieuvre, Didier ;

Mosser, Jean ;

Lena, Herve ;

Ouafik, L'Houcine ;

Besse, Benjamin ;

Rouquette, Isabelle ;

Westeel, Virginie ;

Escande, Fabienne ;

Monnet, Isabelle ;

Lemoine, Antoinette ;

Veillon, Remi ;

Blons, Helene ;

Audigier-Valette, Clarisse ;

Bringuier, Pierre-Paul ;

Lamy, Regine ;

Beau-Faller, Michele ;

Pujol, Jean-Louis ;

Sabourin, Jean-Christophe ;

Penault-Llorca, Frederique ;

Denis, Marc G. ;

Lantuejoul, Sylvie ;

Morin, Franck ;

Quan Tran ;

Missy, Pascale ;

Langlais, Alexandra ;

Milleron, Bernard ;

Cadranel, Jacques ;

Soria, Jean-Charles ;

Zalcman, Gerard .

LANCET, 2016, 387 (10026) :1415-1426

[2] Clinical Benefit From Pemetrexed Before and After Crizotinib Exposure and From Crizotinib Before and After Pemetrexed Exposure in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer [J].

Berge, Eamon M. ;

Lu, Xian ;

Maxson, Delee ;

Baron, Anna E. ;

Gadgeel, Shirish M. ;

Solomon, Benjamin J. ;

Doebele, Robert C. ;

Varella-Garcia, Maria ;

Camidge, D. Ross .

CLINICAL LUNG CANCER, 2013, 14 (06) :636-643

[3] Response to Crizotinib Rechallenge after Initial Progression and Intervening Chemotherapy in ALK Lung Cancer [J].

Browning, Eiko Theodora ;

Weickhardt, Andrew James ;

Camidge, D. Ross .

JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (03) :E21-E22

[4] Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis [J].

Chiari, Rita ;

Metro, Giulio ;

Iacono, Daniela ;

Bellezza, Guido ;

Rebonato, Alberto ;

Dubini, Alessandra ;

Sperduti, Isabella ;

Bennati, Chiara ;

Paglialunga, Luca ;

Burgio, Marco Angelo ;

Baglivo, Sara ;

Giusti, Raffaele ;

Minotti, Vincenzo ;

Delmonte, Angelo ;

Crino, Lucio .

LUNG CANCER, 2015, 90 (02) :255-260

[5] Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study [J].

Gadgeel, Shirish M. ;

Gandhi, Leena ;

Riely, Gregory J. ;

Chiappori, Alberto A. ;

West, Howard L. ;

Azada, Michele C. ;

Morcos, Peter N. ;

Lee, Ruey-Min ;

Garcia, Linta ;

Yu, Li ;

Boisserie, Frederic ;

Di Laurenzio, Laura ;

Golding, Sophie ;

Sato, Jotaro ;

Yokoyama, Shumpei ;

Tanaka, Tomohiro ;

Ou, Sai-Hong Ignatius .

LANCET ONCOLOGY, 2014, 15 (10) :1119-1128

[6] Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib [J].

Gainor, Justin F. ;

Tan, Daniel S. W. ;

De Pas, Tomasso ;

Solomon, Benjamin J. ;

Ahmad, Aziah ;

Lazzari, Chiara ;

de Marinis, Filippo ;

Spitaleri, Gianluca ;

Schultz, Katherine ;

Friboulet, Luc ;

Yeap, Beow Y. ;

Engelman, Jeffrey A. ;

Shaw, Alice T. .

CLINICAL CANCER RESEARCH, 2015, 21 (12) :2745-2752

[7] Stereotactic Radiation Therapy can Safely and Durably Control Sites of Extra-Central Nervous System Oligoprogressive Disease in Anaplastic Lymphoma Kinase-Positive Lung Cancer Patients Receiving Crizotinib [J].

Gan, Gregory N. ;

Weickhardt, Andrew J. ;

Scheier, Benjamin ;

Doebele, Robert C. ;

Gaspar, Laurie E. ;

Kavanagh, Brian D. ;

Camidge, D. Ross .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 88 (04) :892-898

[8] Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial [J].

Gettinger, Scott N. ;

Bazhenova, Lyudmila A. ;

Langer, Corey J. ;

Salgia, Ravi ;

Gold, Kathryn A. ;

Rosell, Rafael ;

Shaw, Alice T. ;

Weiss, Glen J. ;

Tugnait, Meera ;

Narasimhan, Narayana I. ;

Dorer, David J. ;

Kerstein, David ;

Rivera, Victor M. ;

Clackson, Timothy ;

Haluska, Frank G. ;

Camidge, David Ross .

LANCET ONCOLOGY, 2016, 17 (12) :1683-1696

[9] Pharmacokinetics of crizotinib in NSCLC patients [J].

Hamilton, Gerhard ;

Rath, Barbara ;

Burghuber, Otto .

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2015, 11 (05) :835-842

[10] Effects of smoking on the pharmacokinetics of erlotinib [J].

Hamilton, M ;

Wolf, JL ;

Rusk, J ;

Beard, SE ;

Clark, GM ;

Witt, K ;

Cagnoni, PJ .

CLINICAL CANCER RESEARCH, 2006, 12 (07) :2166-2171

← 1 2 3 →